DCPH - Deciphera's GIST Approval And Other News: The Good Bad And Ugly Of Biopharma
Deciphera Receives FDA Approval for GIST Therapy
Deciphera Pharmaceuticals (DCPH) reported that it has received an early FDA approval for Qinlock for treating patients with gastrointestinal stromal tumor (GIST). The treatment is specifically targeted at patients who did not response to at least three previous treatments. The FDA approval came around three months earlier than anticipated. This is the first FDA nod for the company.
Deciphera Pharmaceuticals stated that Qinlock is a kinase inhibitor. The drug candidate was given a breakthrough therapy designation, Priority Review tag as well as fast track tag. The